See more : Revitalist Lifestyle and Wellness Ltd. (RVLWF) Income Statement Analysis – Financial Results
Complete financial analysis of Tandem Diabetes Care, Inc. (TNDM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tandem Diabetes Care, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Valaris Limited WT (VAL-WT) Income Statement Analysis – Financial Results
- China Tourism Group Duty Free Corporation Limited (1880.HK) Income Statement Analysis – Financial Results
- Meggitt PLC (MGGT.L) Income Statement Analysis – Financial Results
- Giga Metals Corporation (HNCKF) Income Statement Analysis – Financial Results
- Asian Sea Corporation Public Company Limited (ASIAN.BK) Income Statement Analysis – Financial Results
Tandem Diabetes Care, Inc. (TNDM)
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 747.72M | 801.22M | 702.80M | 498.83M | 362.31M | 183.87M | 107.60M | 84.25M | 72.85M | 49.72M | 29.01M | 2.47M | 0.00 |
| Cost of Revenue | 380.03M | 388.23M | 326.58M | 238.31M | 168.09M | 94.04M | 63.51M | 60.66M | 46.27M | 34.47M | 22.84M | 3.82M | 0.00 |
| Gross Profit | 367.69M | 412.99M | 376.22M | 260.52M | 194.21M | 89.82M | 44.09M | 23.59M | 26.58M | 15.25M | 6.17M | -1.35M | 0.00 |
| Gross Profit Ratio | 49.17% | 51.54% | 53.53% | 52.23% | 53.60% | 48.85% | 40.98% | 28.00% | 36.49% | 30.67% | 21.26% | -54.48% | 0.00% |
| Research & Development | 169.67M | 139.11M | 92.05M | 63.57M | 45.20M | 29.23M | 20.66M | 18.81M | 16.96M | 15.79M | 11.08M | 9.01M | 8.26M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.38M | 82.83M | 78.62M | 75.12M | 43.82M | 22.62M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.50M | 700.00K | 68.00K | 0.00 |
| SG&A | 352.50M | 335.68M | 261.51M | 204.90M | 165.74M | 105.23M | 86.38M | 82.83M | 78.62M | 75.12M | 44.52M | 22.69M | 15.95M |
| Other Expenses | 78.75M | -4.00K | 0.00 | 0.00 | -7.88M | -77.93M | -10.08M | -5.41M | -3.40M | -3.79M | 44.52M | 22.69M | 0.00 |
| Operating Expenses | 600.92M | 474.80M | 353.56M | 268.48M | 210.93M | 134.45M | 107.04M | 101.64M | 95.58M | 90.91M | 55.60M | 31.70M | 24.21M |
| Cost & Expenses | 980.95M | 863.03M | 680.15M | 506.79M | 379.03M | 228.50M | 170.55M | 162.30M | 141.85M | 125.39M | 78.44M | 35.52M | 24.21M |
| Interest Income | 22.86M | 6.06M | 674.00K | 1.57M | 3.27M | 1.46M | 239.00K | 296.00K | 337.00K | 112.00K | 6.64K | 2.43K | 13.66K |
| Interest Expense | 9.88M | 4.31M | 4.31M | 12.15M | 78.00K | 7.58M | 11.34M | 5.71M | 3.74M | 3.90M | 4.71M | 2.53M | 542.18K |
| Depreciation & Amortization | 15.72M | 14.33M | 13.85M | 10.45M | 6.07M | 5.82M | 6.87M | 5.49M | 4.83M | 4.39M | 3.17M | 2.03M | 1.28M |
| EBITDA | -194.66M | -72.31M | 36.50M | -13.03M | -18.45M | -109.16M | -54.82M | -72.27M | -63.84M | -71.16M | -55.26M | -28.46M | -22.92M |
| EBITDA Ratio | -26.03% | -3.84% | 3.22% | -1.60% | -4.62% | -24.27% | -58.50% | -92.64% | -94.72% | -152.17% | -159.48% | -1,253.23% | 0.00% |
| Operating Income | -233.23M | -61.81M | 8.81M | -7.96M | -16.72M | -44.63M | -62.94M | -78.05M | -69.00M | -75.66M | -49.43M | -33.05M | -24.21M |
| Operating Income Ratio | -31.19% | -7.71% | 1.25% | -1.60% | -4.62% | -24.27% | -58.50% | -92.64% | -94.72% | -152.17% | -170.42% | -1,335.44% | 0.00% |
| Total Other Income/Expenses | 12.98M | -4.00K | -6.75M | -28.33M | -7.88M | -77.93M | -10.08M | -5.41M | -3.40M | -3.79M | -13.70M | 33.00K | -1.30M |
| Income Before Tax | -220.25M | -92.85M | 15.90M | -36.28M | -24.60M | -122.56M | -73.03M | -83.46M | -72.41M | -79.45M | -63.14M | -33.02M | -25.51M |
| Income Before Tax Ratio | -29.46% | -11.59% | 2.26% | -7.27% | -6.79% | -66.66% | -67.87% | -99.07% | -99.39% | -159.79% | -217.67% | -1,334.11% | 0.00% |
| Income Tax Expense | 2.36M | 1.74M | 335.00K | -1.90M | 149.00K | 51.00K | 8.00K | -15.00K | 10.00K | 71.00K | 4.71M | 2.53M | 542.18K |
| Net Income | -222.61M | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M | -73.03M | -83.45M | -72.42M | -79.52M | -63.14M | -33.02M | -25.51M |
| Net Income Ratio | -29.77% | -11.81% | 2.21% | -6.89% | -6.83% | -66.68% | -67.87% | -99.05% | -99.41% | -159.94% | -217.67% | -1,334.11% | 0.00% |
| EPS | -3.43 | -1.47 | 0.25 | -0.56 | -0.42 | -2.55 | -12.86 | -27.30 | -25.04 | -34.17 | -214.61 | -26.32 | -20.34 |
| EPS Diluted | -3.43 | -1.47 | 0.24 | -0.56 | -0.42 | -2.55 | -12.86 | -27.30 | -25.04 | -34.17 | -214.61 | -26.32 | -20.34 |
| Weighted Avg Shares Out | 64.90M | 64.15M | 63.00M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M | 2.89M | 2.33M | 294.20K | 1.25M | 1.25M |
| Weighted Avg Shares Out (Dil) | 64.97M | 64.15M | 64.35M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M | 2.89M | 2.33M | 294.20K | 1.25M | 1.25M |
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
Tandem Diabetes Care, Inc. (TNDM) Q2 2024 Earnings Call Transcript
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions
Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer
The 3 Best Diabetes Stocks to Buy in June 2024
Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association's 84th Scientific Sessions
Source: https://incomestatements.info
Category: Stock Reports